Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments

A growing body of research indicates that psychedelics are safe and potentially effective as treatments for a wide range of psychiatric disorders. Between 2019 and 2020, investments ballooned from about $60 million to over $600 million. 

Compound DMT
Visit article
Category Press Release
Country Canada

Companies Featured

Entheon Biomedical
Entheon Biomedical is a listed (CSE) company that aims to develop DMT for addiction treatment.

?>